Hormonoterapia adyuvante en cáncer de mama. Revisión de la Evidencia y Abordaje Terapéutico en el Instituto Instituto Nacional de Cancerología, Bogotá, Colombia

Breast cancer is the most frequently diagnosed cancer in women around the planet. According to GLOBOCAN 2020, its incidence and mortality worldwide are calculated at 47.8 and 13.6 per 100,000 women, respectively; for Colombia, the estimated incidence rate is 48.3 per 100,000 women, while mortality is 13.1 per 100,000 women. About 70% of breast cancer expresses hormone receptors (HR+) and is amenable to management with hormonal therapy, which improves the clinical outcomes of patients in the adjuvant and metastatic settings. Specifically in the adjuvant setting, studies have shown that hormonal therapy reduces the risk of relapse by almost 50% and the risk of death by 30%, after 10 years of follow-up. For this update, a literature search was carried out in two of the most important bibliographic databases, subsequently selecting the most relevant clinical trials, systematic reviews, and meta-analyses on the subject. Finally, joint meetings were held between the functional units for breast and soft tissue tumors and clinical oncology of the National Cancer Institute of Colombia (INC), which managed to establish the therapeutic approach for adjuvant treatment in pre-and postmenopausal patients with HR+ breast cancer, considering each recommendation in relation to the risk of disease relapse.